文献速递毛发、甲与色素性疾病

伊伐替尼治疗中重度斑秃的随机双盲安慰剂对照II期研究

A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
PubMed 文献 · J Am Acad Dermatol · 2023-04-03

该随机双盲安慰剂对照II期研究纳入94例脱发面积≥25%的成人斑秃患者,按1:1:1:1分为伊伐替尼2、4、8 mg每日一次组和安慰剂组治疗24周。主要终点为第24周脱发严重程度工具评分较基线的百分比变化。结果显示4 mg和8 mg剂量有效且总体耐受。

要点

  • 伊伐替尼4 mg和8 mg治疗24周对中重度斑秃有效。
  • 第24周SALT评分较基线变化:4 mg组-56.11%,8 mg组-51.01%,2 mg组-30.51%,安慰剂组-19.87%。
  • 报告两例严重不良事件:滤泡性淋巴瘤和COVID-19肺炎。

核心结论

  • 伊伐替尼4 mg和8 mg剂量治疗中重度斑秃患者24周有效且总体耐受。

研究设计与样本

  • 随机、双盲、安慰剂对照II期研究,94例脱发面积≥25%的成人斑秃患者按1:1:1:1随机接受伊伐替尼2、4、8 mg每日一次或安慰剂治疗24周。

主要发现

  • 第24周SALT评分较基线百分比变化的最小二乘均值差:伊伐替尼2 mg组-30.51%(90% CI,-45.25,-15.76),4 mg组-56.11%(90% CI,-70.28,-41.95),8 mg组-51.01%(90% CI,-65.20,-36.82),安慰剂组-19.87%(90% CI,-33.99,-5.75)。
  • 报告两例严重不良事件:滤泡性淋巴瘤和COVID-19肺炎。

关键数值与推荐

  • 主要终点为第24周SALT评分较基线的百分比变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量小限制了结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alopecia areata (AA) is a CD8+ T cell-mediated autoimmune disease characterized by nonscarring hair loss. Ivarmacitinib, which is a selective oral Janus kinase 1 inhibitor, may interrupt certain cytokine signaling implicated in the pathogenesis of AA. OBJECTIVE: To evaluate the efficacy and safety of ivarmacitinib in adult patients with AA who have ≥25% scalp hair loss. METHODS: Eligible patients were randomized 1:1:1:1 to receive ivarmacitinib 2, 4, or 8 mg once daily or placebo for 24 weeks. The primary end point was the percentage change from baseline in the Severity of Alopecia Tool score at week 24. RESULTS: A total of 94 patients were randomized. At week 24, the least squares mean difference in the percentage change from baseline in the Severity of Alopecia Tool score for ivarmacitinib 2, 4, and 8 mg and placebo groups were -30.51% (90% CI, -45.25, -15.76), -56.11% (90% CI, -70.28, -41.95), -51.01% (90% CI, -65.20, -36.82), and -19.87% (90% CI, -33.99, -5.75), respectively. Two serious adverse events-follicular lymphoma and COVID-19 pneumonia-were reported. LIMITATIONS: A small sample size limits the generalizability of the results. CONCLUSION: Treatment with ivarmacitinib 4 and 8 mg doses in patients with moderate and severe AA for 24 weeks was efficacious and generally tolerated.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Yang X, Yang B, et al. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol. 2023. PMID: 37019385. doi:10.1016/j.jaad.2023.02.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。